A couple of weeks ago, the Los Angeles Times ran a big package about generic meds. Are they really as good as the brand-name versions [1]? Well, the FDA can answer that question about one generic in particular today. The agency asked Caraco Pharmaceutical Laboratories, the U.S. subsidiary of Indian generics giant Sun Pharmaceuticals, to withdraw its diabetes med metformin hydrochloride, "citing efficacy and quality issues," the Business Standard reports.

Caraco will have to withdraw seven lots of the metformin because some tablets were too small and others too big, so like Goldilocks, patients might not have received the correct dose.

- read the Business Standard article [2]
- check out the generics coverage [3] at the LA Times

Related Articles:
Study: Costlier drug worked better. Report [4]
Insurers pay docs for generic-switching. Report [5]
Generics beat down drug price inflation. Report [6]
Op-Ed: Generics aren't always equal. Report [7]
Detroit wins bid for big Caraco expansion. Report [8]